Tower Research Capital LLC (Trc) Neu Base Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.17 - $0.39 $1 - $3	10 Added 0.06%	17,777 $3,000
Q4 2022 Feb 10, 2023	BUY	$0.18 - $0.3 $884 - $1,474	4,916 Added 38.25%	17,767 $3,000
Q3 2022 Nov 10, 2022	BUY	$0.41 - $1.3 $4,469 - $14,170	10,900 Added 558.69%	12,851 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $8,299 - $19,533	-10,121 Reduced 83.84%	1,951 $2,000
Q1 2022 May 12, 2022	SELL	$1.26 - $2.95 $9,919 - $23,225	-7,873 Reduced 39.47%	12,072 $23,000
Q4 2021 Feb 14, 2022	BUY	$2.6 - $4.18 $48,154 - $77,417	18,521 Added 1300.63%	19,945 $56,000
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $12,694 - $18,478	-3,882 Reduced 73.16%	1,424 $5,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $16,751 - $26,556	-3,618 Reduced 40.54%	5,306 $25,000
Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $22,981 - $41,047	3,321 Added 59.27%	8,924 $66,000
Q4 2020 Feb 16, 2021	SELL	$6.92 - $9.25 $72,120 - $96,403	-10,422 Reduced 65.04%	5,603 $39,000
Q3 2020 Nov 16, 2020	BUY	$7.25 - $9.71 $89,900 - $120,404	12,400 Added 342.07%	16,025 $122,000
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $24,251 - $41,723	3,625 New	3,625 $32,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.